IHL

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Retrieved on: 
Thursday, December 21, 2023

MELBOURNE, Australia and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that it has received ethics board endorsement for psychedelic assisted therapy at its first clinic based in Melbourne, Australia, a city of approximately 5.2M people.

Key Points: 
  • Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD.
  • Clarion Clinics is the only dedicated psychedelic-assisted therapy clinic in Australia, with intentions to open more clinics across the country and internationally as legislation permits.
  • Clarion Clinics team includes pre-eminent psychedelic researchers, psychologists and psychiatrists whose expertise can not easily be replicated in Australia.
  • The Melbourne Clarion Clinic will be the first dedicated Psychedelic-assisted therapy clinic in Australia.

What is the rule of proportionality, and is it being observed in the Israeli siege of Gaza?

Retrieved on: 
Thursday, November 9, 2023

More than a month after Hamas fighters killed 1,400 Israelis in a shock assault, bombs continue to fall on the Gaza Strip in reprisal Israeli attacks.

Key Points: 
  • More than a month after Hamas fighters killed 1,400 Israelis in a shock assault, bombs continue to fall on the Gaza Strip in reprisal Israeli attacks.
  • “Proportionality” has a place in what is described as the “laws of war.” The Conversation turned to Robert Goldman, an expert on international humanitarian law at American University Washington College of Law, for guidance on some of the issues.

What are the ‘laws of war’?

  • It also includes what is known as “customary law” – rules that are accepted by states a legally binding, but are not necessarily part of any formal treaty.
  • It is important to understand that modern IHL is not concerned with the reasons for, or the legality of, going to war.

Can civilian structures ever be lawfully attacked?

  • This is because they, unlike munitions factories and command and control centers, do not effectively contribute to military action.
  • If enemy forces take up positions in these civilian structures, then they become military objectives and can be lawfully bombed if the raid would yield the attacking party a definite military advantage.

What exactly is the rule of proportionality?

  • The rule of proportionality applies to all armed conflicts as part of customary IHL.
  • As such, the rule does not apply to enemy combatants or civilians who are directly participating in hostilities.
  • Such a determination requires a balancing of probabilities that take in foreseeable collateral civilian casualties and the relative importance of a particular military target.
  • In addition, planners of a particular attack must choose a weapon that ideally will avoid or minimize likely civilian collateral damage.
  • As such, the rule or proportionality requires the attacking party to place high priority on the timely collection and evaluation of target intelligence.

Is the rule of proportionality being observed in Gaza?

  • That analysis should be based on timely, reliable and constantly updated target intelligence.
  • Israeli military spokesmen have stated repeatedly that they are taking all feasible measures to avoid excessive collateral damage in their bombing campaign.
  • Part of this article appeared in an earlier article published by The Conversation on Oct. 15, 2023.


Robert Goldman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq

Retrieved on: 
Monday, July 10, 2023

MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) --  Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), (Incannex, IHL or the Company) is pleased to announce its intention to redomicile from Australia to the United States via proposed schemes of arrangement (Schemes) between Incannex and its shareholders (Share Scheme) and Incannex and its optionholders (Option Scheme). Implementation of the Schemes is subject to approval of IHL's shareholders (in respect of the Share Scheme) and IHL's optionholders (in respect of the Option Scheme) and other regulatory and court approvals.

Key Points: 
  • Incannex has already achieved registration of its ordinary shares from the US Securities and Exchange Commission (SEC).
  • Since February 2022, Incannex’s ordinary shares, in the form of American Depository Receipts (ADRs), have been trading in the United States since gaining Nasdaq Global market listing status.
  • Pursuant to the Share Scheme:
    holders of fully paid ordinary shares in Incannex (Incannex Shares) will be entitled to receive one share of common stock in Incannex US (Incannex US Share) for every 100 Incannex Shares held on the record date for the Share Scheme; and
    holders of Incannex ADRs will be entitled to receive one Incannex US Share for every four ADRs (each ADR currently represents 25 Incannex Shares) held in Incannex on the Share Scheme record date.
  • Incannex has engaged Thomson Geer to assist in the implementation of the Schemes and Rimôn Law to assist in the Nasdaq listing of Incannex US.

Ukraine war: what international law says about the Russians fighting against their own country

Retrieved on: 
Thursday, June 15, 2023

Ground raids in the Belgorod region of Russia, adjacent to the north-eastern frontier of Ukraine, appear to have upped the ante.

Key Points: 
  • Ground raids in the Belgorod region of Russia, adjacent to the north-eastern frontier of Ukraine, appear to have upped the ante.
  • It creates legal complications in international humanitarian law (IHL) that will be difficult to untangle unless responsibility for the operations can be definitively attributed.

Who is involved

    • The incursions have been carried out, according to Ukrainian officials, by two separate groups of Russian citizens.
    • These are the Freedom of Russia Legion (FRL) and the Russian Volunteer Corps (RVC).
    • Its status is unclear when it comes to the group’s relationship with Ukraine’s military command and control.
    • The answers to these questions determine whether captured fighters are protected under IHL, and who will be held accountable for their actions.

Irregular fighters and international law

    • The participation of irregular units in armed conflict has been a persistent feature of warfare since at least the Peninsular War (1808-1814).
    • The development of international law to reflect this reality of modern warfare was further spurred by the French use of francs-tireurs (literally, “free-shooters”) in occupied areas of north-eastern France during the Franco-Prussian war (1870-1871).
    • In the second Anglo-Boer war (1899-1902), meanwhile, the entire army of the Boer republics consisted of irregular farmers who were mobilised into kommandos to resist the British invasion.
    • This defines entitlement after capture to the rights and protections of prisoners of war (POWs).
    • A notable feature of that conflict had been the activities of armed resistance movements in occupied territory.
    • And if the FRL has been incorporated into the Ukrainian Foreign Legion, as has been reported, its fighters should be considered part of the Ukrainian armed forces.
    • Because they come under the IHL definition of combatants, they should be protected from being treated as saboteurs after capture, which carries a heavy penalty under Russian law.

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Retrieved on: 
Tuesday, May 30, 2023

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a pharmaceutical company developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and an operator of psychedelic-assisted psychotherapy clinics, is pleased to announce that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.

Key Points: 
  • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.
  • The company is delighted to announce that, in addition to the most experienced psychedelics professionals in Australia taking key executive roles and directorships in the Clarion Clinics Group, three of the world’s most experienced and leading clinical psychedelic experts have joined its Advisory Board.
  • Andrea serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation.
  • I’m grateful for their trust and support.”
    Peter Widdows, Incannex Director, said: “I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team.

Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts

Retrieved on: 
Thursday, March 16, 2023

MELBOURNE, Australia, March 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL). (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that it has developed plans for the commercialisation of its psychedelic-assisted psychotherapy business (‘Psychedelic Clinics’).

Key Points: 
  • Incannex owned subsidiary is being led by long time Incannex director, Mr Peter Widdows.
  • (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that it has developed plans for the commercialisation of its psychedelic-assisted psychotherapy business (‘Psychedelic Clinics’).
  • Peter Widdows, Incannex Director and psychedelic clinics business lead said: “We initially intended to use only ketamine-assisted psychotherapy, with the possibility of expanding into psilocybin-assisted psychotherapy for Generalised Anxiety Disorder subject to regulatory approval.
  • I’m grateful to Incannex for providing the resources to do this work and trusting us to build the clinics of the future.

Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

Retrieved on: 
Wednesday, March 15, 2023

MELBOURNE, Australia, March 15, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical cannabinoid and psychedelic medicines company, is pleased to announce results of an interim review of the conduct, safety and data from its ongoing Phase 2 clinical trial assessing its proprietary psilocybin-assisted psychotherapy program for Generalised Anxiety Disorder (‘GAD’), known as “PsiGAD”.

Key Points: 
  • An independent Data Safety Monitoring Board (DSMB) has reviewed data from Incannex’s ongoing Phase 2 “PsiGAD” clinical trial and recommends no changes to study design.
  • IHL has reviewed the interim data from the first 29 participants to complete the treatment protocol and completed a conditional power analysis using the interim data to model and project total study data.
  • The trial team have identified no safety concerns to date, and the DSMB has recommended that the trial continues without changes.
  • Treatment of all 72 trial participants is anticipated to be completed in the fourth quarter of 2023.

Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer

Retrieved on: 
Thursday, January 26, 2023

Innocoll Holdings Ltd. (“IHL”), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital (“GPC”), today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer.

Key Points: 
  • Innocoll Holdings Ltd. (“IHL”), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital (“GPC”), today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer.
  • As part of this appointment, Kimball will also serve as Chief Executive Officer of IHL’s two subsidiaries: Syntacoll GmbH (“Syntacoll”), a contract development and manufacturing organization (“CDMO”) specializing in collagen-based technology platforms, and Innocoll Biotherapeutics Inc. (“Innocoll”), a global biotech company focusing on delivering non-opioid alternatives for postsurgical pain management.
  • View the full release here: https://www.businesswire.com/news/home/20230126005290/en/
    With over 30 years of commercial operations experience, Kimball has proven expertise developing, licensing, and supplying biopharmaceutical products for global markets.
  • At IHL, Kimball will lead all functions across both Syntacoll and Innocoll.

NRF 2023: Retail Pro Prism resolves bottlenecks and rebuilds customer relationships for retailers

Retrieved on: 
Monday, January 16, 2023

Now it’s time to apply those learnings and iron out the inefficiencies that are keeping them from rebuilding customer relationships,” said Retail Pro International CEO, Kerry Lemos.

Key Points: 
  • Now it’s time to apply those learnings and iron out the inefficiencies that are keeping them from rebuilding customer relationships,” said Retail Pro International CEO, Kerry Lemos.
  • That’s where the Retail Pro Prism platform comes in.”
    With Retail Pro Prism, retailers can serve customer needs better by:
    In addition to the efficiencies gained in building core retail operations on Retail Pro Prism, retailers can integrate other retail technologies with the Retail Pro Prism platform for a holistic view of their data that will help them understand and respond to customer needs.
  • “OptCulture Marketing for Retail Pro empowers retailers to keep investing in customer relationships with meaningful offers and rewards for shopper loyalty.
  • Retailers are invited to visit the Retail Pro booth (#6203) at NRF 2023 on January 15 – 17 to discuss their operational needs and see how the Retail Pro Prism solution can help them rebuild customer relationships.

ToolsGroup-IHL Group 2022 Retail Inventory Study Shows Diminishing Customer Loyalty Due to Out-of-Stock Concerns

Retrieved on: 
Thursday, September 29, 2022

BOSTON, Sept. 29, 2022 /PRNewswire/ -- ToolsGroup, a global leader in AI-driven retail and supply chain planning and optimization software, in collaboration with IHL Group, a global research and advisory firm for the retail and hospitality industries, today released a study on the role of inventory in consumer loyalty and what retailers can do to win and keep customers.

Key Points: 
  • In July 2022, IHL and ToolsGroup surveyed U.S. consumers on their loyalty to and trust of retailers, as well as their reasons for choosing online or in-store shopping.
  • Across other retail sectors, customers have increased their trust in inventory availability from 1-7%.
  • These include AI-supported retail planning software such as demand forecasting , inventory optimization , real-time inventory visibility, and order fulfillment optimization to create a healthy inventory balance.
  • IHL Group is a global research and advisory firm specializing in technologies for the retail and hospitality industries.